ConductScience.org, home

Paper38780656

Combined hepatocellular-cholangiocarcinoma: from genesis to molecular pathways and therapeutic strategies.

Gurzu S and 3 others. J Cancer Res Clin Oncol, 2024. Cited by 14 papers, by iCite.

Cite this record

ConductScience Library. Combined hepatocellular-cholangiocarcinoma: from genesis to molecular pathways and therapeutic strategies. Papers, record 38780656. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/38780656

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Combined hepatocellular-cholangiocarcinoma: from genesis to molecular pathways and therapeutic strategies.
PubMed
Journal
J Cancer Res Clin Oncol
PubMed
Year
2024
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
14
iCite
Relative citation ratio, by iCite
1.69, provisional
iCite
Revised in PubMed
2024-06-11
PubMed

Authors4

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Gurzu SSimona
2Szodorai RRita
3Jung IIoan
4Banias LLaura

Source PubMed

Download CSV of authors

Topics5

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
CholangiocarcinomaMajor topic
Carcinoma, HepatocellularMajor topic
Liver NeoplasmsMajor topic
Bile Duct NeoplasmsMajor topic
Humans

References67

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
130967907Angiogenesis of hepatocellular carcinoma: An immunohistochemistry study.World J Hepatol2019https://conductscience.org/library/papers/30967907PubMed
221744084Clinical and pathological analysis of 27 patients with combined hepatocellular-cholangiocarcinoma in an Asian center.J Hepatobiliary Pancreat Sci2012https://conductscience.org/library/papers/21744084PubMed
323034166Comparison of clinical characteristics of combined hepatocellular-cholangiocarcinoma and other primary liver cancers.J Gastroenterol Hepatol2013https://conductscience.org/library/papers/23034166PubMed
434213048Long-Term Survival of Combined Hepatocellular-Cholangiocarcinoma: A Nationwide Study.Oncologist2021https://conductscience.org/library/papers/34213048PubMed
527812807Clinicopathological Features and Post-resection Prognosis of Double Primary Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma.World J Surg2017https://conductscience.org/library/papers/27812807PubMed
618407604Clinicopathologic characteristics of intrahepatic cholangiocarcinoma in patients with positive serum a-fetoprotein.World J Gastroenterol2008https://conductscience.org/library/papers/18407604PubMed
723900502Elevated expression of cyclooxygenase-2 and microsomal prostaglandin E synthase-1 in primary sclerosing cholangitis: ιmplications for cholangiocarcinogenesis.Int J Oncol2013https://conductscience.org/library/papers/23900502PubMed
827320566Combined Hepatocellular Carcinoma and Cholangiocarcinoma: Diagnosis and Prognosis After Resection or Transplantation.Transplant Proc2016https://conductscience.org/library/papers/27320566PubMed
923166536S100 proteins as diagnostic and prognostic markers in colorectal and hepatocellular carcinoma.Hepat Mon2012https://conductscience.org/library/papers/23166536PubMed
1028765978Imaging features of hepatocellular carcinoma compared to intrahepatic cholangiocarcinoma and combined tumor on MRI using liver imaging and data system (LI-RADS) version 2014.Abdom Radiol (NY)2018https://conductscience.org/library/papers/28765978PubMed
1132508620Checkpoint Inhibition Causing Complete Remission of Metastatic Combined Hepatocellular-Cholangiocarcinoma after Hepatic Resection.Case Rep Oncol2020https://conductscience.org/library/papers/32508620PubMed
1226200629Atypical Hepatocellular Neoplasm With Peliosis in Cirrhotic Liver Versus Hepatocellular Carcinoma: A Diagnostic Trap.Medicine (Baltimore)2015https://conductscience.org/library/papers/26200629PubMed
1337900166Case report: Remarkable response to sintilimab, lenvatinib, and nab-paclitaxel in postoperative metastatic chemotherapy-resistant combined hepatocellular-cholangiocarcinoma.Front Pharmacol2023https://conductscience.org/library/papers/37900166PubMed
1438432964Unresectable Combined Hepatocellular-cholangiocarcinoma Treated with Combination Therapy Consisting of Durvalumab Plus Tremelimumab.Intern Med2024https://conductscience.org/library/papers/38432964PubMed
1526109824Primary combined hepatocellular-cholangiocellular sarcoma: An unusual case.World J Gastroenterol2015https://conductscience.org/library/papers/26109824PubMed
162578078Combined hepatocellular-cholangiocarcinoma. A histologic and immunohistochemical study.Cancer1985https://conductscience.org/library/papers/2578078PubMed
1726917546Combined hepatocellular carcinoma and cholangiocarcinoma (biphenotypic) tumors: clinical characteristics, imaging features of contrast-enhanced ultrasound and computed tomography.BMC Cancer2016https://conductscience.org/library/papers/26917546PubMed
1826496332Significant Shrinkage of Multifocal Liver Metastases and Long-Term Survival in a Patient With Rectal Cancer, After Trans-Arterial Chemoembolization (TACE): A Case Report.Medicine (Baltimore)2015https://conductscience.org/library/papers/26496332PubMed
1924777610Combined hepatocellular-cholangiocarcinoma: a population-level analysis of an uncommon primary liver tumor.Liver Transpl2014https://conductscience.org/library/papers/24777610PubMed
2032173767Benefits of the 8th American Joint Committee on Cancer System for Hepatocellular Carcinoma Staging.J Gastrointest Cancer2021https://conductscience.org/library/papers/32173767PubMed

See all 67 referencesDownload CSV of references

Cited by14

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 14 citations.

PMIDTitleJournalYearIn PapersSource
42857008Hepatocellular- cholangiocarcinoma collision tumor: a case report.Front Oncol2026https://conductscience.org/library/papers/42857008PubMed
42450313Programmed Death Ligand 1 (PD-L1) and Tumor-Associated Macrophages in Gastric-Type Hepatocellular Carcinoma: Prognostic Insights.Int J Mol Sci2026https://conductscience.org/library/papers/42450313PubMed
42063578From organelles to therapy: rethinking combined hepatocellular-cholangiocarcinoma.Front Cell Dev Biol2026https://conductscience.org/library/papers/42063578PubMed
42057824Long-term complete remission of metastatic combined hepatocellular-cholangiocarcinoma with nivolumab following failure of targeted therapies: a case report.Front Oncol2026https://conductscience.org/library/papers/42057824PubMed
41802450Combined hepatocellular-cholangiocarcinoma: a contemporary pathologic and molecular perspective.J Liver Cancer2026https://conductscience.org/library/papers/41802450PubMed
41597200Establishment of Patient-Derived Organoids from Hepatocellular Carcinoma: Preliminary Data on Yield, Histopathological Concordance, and Methodological Challenges.Cells2026https://conductscience.org/library/papers/41597200PubMed
41464759Outcomes of Liver Transplantation in Incidental Intrahepatic Cholangiocarcinoma and Combined Hepatocellular-Cholangiocarcinoma: An Exceptional Perspective from a Single-Center Experience.J Clin Med2025https://conductscience.org/library/papers/41464759PubMed
41037071Intratumoral heterogeneity of CT enhancement for component prediction and prognostic significance in combined hepatocellular carcinoma‑cholangiocarcinoma.Eur Radiol2026https://conductscience.org/library/papers/41037071PubMed
40843884Radiologic and Pathologic Insights in Combined Hepatocellular-Cholangiocarcinoma: A Report of Three Cases.Reports (MDPI)2025https://conductscience.org/library/papers/40843884PubMed
40502515Liver transplantation for combined hepatocellular cholangiocarcinoma: Current evidence, selection criteria, and therapeutic controversies.World J Gastrointest Surg2025https://conductscience.org/library/papers/40502515PubMed
40324881The rise of RAS: how gradual oncogene activation shapes the OIS spectrum.Genes Dev2025https://conductscience.org/library/papers/40324881PubMed
40196844HTRecNet: a deep learning study for efficient and accurate diagnosis of hepatocellular carcinoma and cholangiocarcinoma.Front Cell Dev Biol2025https://conductscience.org/library/papers/40196844PubMed
39948704Synchronous Hepatocellular and Intrahepatic Cholangiocellular Carcinoma With Predominant Ductal Plate Malformation Pattern. A Case Report and Review of the Literature.Cancer Rep (Hoboken)2025https://conductscience.org/library/papers/39948704PubMed
39643892Persistent response to combination therapy of pemigatinib and chemotherapy in a child of combined hepatocellular-cholangiocarcinoma with FGFR2 fusion.Mol Cancer2024https://conductscience.org/library/papers/39643892PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/38780656

GET https://conductscience.org/api/papers/v1/38780656/references?page=2